Contemporary personalized β-blocker management in the perioperative setting.
Adriana D OpreaXiaoxiao WangRobert SickelerMiklos D KertaiPublished in: Journal of anesthesia (2019)
Beta-adrenergic blockers (β-blockers) are clearly indicated for the long-term treatment of patients with systolic heart failure and post-acute myocardial infarction. Early small-scale studies reported their potential benefits for perioperative use; subsequent randomized controlled trials, however, failed to reproduce earlier findings. Furthermore, their role in reducing major postoperative cardiac events following noncardiac and cardiac surgery remains controversial. This case-based review presents an overview of contemporary literature on perioperative β-blocker use with a focus on data available since 2008 when the PreOperative ISchemic Evaluation (POISE) trial was published. Our review suggests that studies should determine the effects of situational-based guidelines on perioperative β-blocker use on the risk of cardiac adverse events and mortality in the perioperative period.
Keyphrases
- cardiac surgery
- patients undergoing
- left ventricular
- heart failure
- acute kidney injury
- angiotensin converting enzyme
- acute myocardial infarction
- randomized controlled trial
- systematic review
- blood pressure
- clinical trial
- cardiovascular events
- study protocol
- risk assessment
- atrial fibrillation
- clinical practice
- case control
- climate change
- brain injury
- open label
- subarachnoid hemorrhage
- smoking cessation
- human health